Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigation of Body Mass Index, Body Composition, Resting Energy Expenditure, Respiratory Quotient and Metabolic Changes Following a Switch From Olanzapine, Quetiapine or Risperidone to Aripiprazole.

Trial Profile

Investigation of Body Mass Index, Body Composition, Resting Energy Expenditure, Respiratory Quotient and Metabolic Changes Following a Switch From Olanzapine, Quetiapine or Risperidone to Aripiprazole.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2014

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Mood disorders; Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Jun 2010 Actual end date (April 2010) added as reported by ClinicalTrials.gov.
    • 21 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Apr 2010 Company added as trial sponsor as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top